PCK2 as a potential therapeutic target for aggressive MYC-amplified non-WNT/non-SHH medulloblastoma based on tumor continuum

Shuaishuai Xue, Zhengming Zhan, Yonghua Cai, Wei Chen, Ruizhe Chen, Yangqi Mao, Cheng Xie, Jun Liu, Ziyi Luo, Siyuan Liu, Xian Zhang, Peng Li, Hao Long, Ye Song · 2026

Read PCK2 as a potential therapeutic target for aggressive MYC-amplified non-WNT/non-SHH medulloblastoma based on tumor continuum by Shuaishuai Xue, Zhengming Zhan, Yonghua Cai, Wei Chen, Ruizhe Chen, Yangqi Mao, Cheng Xie, Jun Liu, Ziyi Luo, Siyuan Liu, Xian Zhang, Peng Li, Hao Long, Ye Song (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13531781.txt.

Description

Shuaishuai Xue and co-authors nominate in 2026 a metabolic gene as a drug target for the most aggressive childhood brain tumor group. Medulloblastoma outside the two calmer families often spreads and resists care, especially with extra copies of the MYC growth gene. Public gene datasets were mined along a spectrum between tumor subtypes.

One energy-pathway gene, PCK2, tracked that spectrum most tightly. Silencing it in tumor cells slowed growth, movement, invasion, and sugar burning, while shifting immune macrophages away from a tumor-friendly state. The findings tie tumor metabolism to its immune surroundings and offer a precision target.

Catalog record

CREATORShuaishuai Xue, Zhengming Zhan, Yonghua Cai, Wei Chen, Ruizhe Chen, Yangqi Mao, Cheng Xie, Jun Liu, Ziyi Luo, Siyuan Liu, Xian Zhang, Peng Li, Hao Long, Ye Song
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39274
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13531781

Browse the full library · About the Tower of Babel